Better Breathing
Spring Edition 2025
A HERO IN MOTION Kath Cross' inspirational story
CALLUM'S
HALF MARATHON RUN FOR ASTHMA
'I LOVE YOU MUMMY...
23-year-old goalkeeper’s fundraising challenge for lung health
PLEASE DON'T DIE TODAY' A mother’s fight against asthma
ICE IDENTIFI
BUDESONI DE
$
$
50 mcg
$
100 mcg Accuhaler®
$
250 mcg
100 mcg
Spiromax®
$
$
$
$
200/6 400/12* Dry powder inhaler
*Symbicort 400/12
Vannair®
$
100/6
200/6
and DuoResp Note: Symbicort Aerosol inhaler Spiromax 400/12 100/6, 200/6 only funded and DuoResp Vannair 100/6 if no more than Spiromax 200/6 and 200/6 is are currently 2 doses per day approved for approved for maintenance Anti-Inflammatory use, but its use Reliever (AIR) in AIR therapy therapy. is an unapproved indication.
Long-Actin g Beta2 Agonists
SALMETERO L
Serevent®
FORMOTER OL (eformotero l)
50 mcg Accuhaler®
M + OLODATER OL
6 mcg Turbuhaler®
UMECLIDIN IUM + VILANTERO L
Anoro Ellipta®
$
150 mcg 300 mcg Breezhaler
62.5 mcg/25 mcg Dry powder
®
GLYCOPYR RONIUM + INDACATER
OL Ultibro® Breezhale r®
$
2.5 mcg/2.5 mcg Fine mist inhaler
$ 50
free to those Contact Manatū Hauora Ministry who need them on a Practitioners Everyone should of Health for Supply Order have an action an order form (PSO). on 0800 353 plan. Find a range of management 2425. plans at asthmafound ation.org.nz
$
Funded by
Low carbon 1. Wurzel DF,
Not funded
endorseme nt
footprint1
Montgomery
BD, Anderson
Seretide®
$
$
Partially funded
Funded by
High carbon N et al. Environmental
Special Authority
footprint1
impact of inhaled
medicines: A
(ultrafine particle)
$
$
$
$
mcg 250 mcg Aerosol inhalers
and Qvar® are
not dose equivalent
+ SALMETERO L
50 mcg 100 mcg and are not
interchangeable.
FLUTICASO NE furoate + VILANTERO L
Breo Ellipta®
$
$
$
50/25
125/25 250/25 Aerosol inhaler
$
$
$
100/50*
250/50* Accuhaler®
$
100/25
*100/50 and 250/50 accuhaler only funded if no more than 2 doses per day
Long-Actin g Muscarinic
TIOTROPIU M
Spiriva®
Spiriva Respimat®
$
mcg/110 mcg Funded via inhaler Special Authority: stabilised on Breezhaler® LAMA + a from switching LAMA and the prescriber LABA inhaler is subsidised combination to a combination product.considers that the patient only for patients who have been ICS and LABA. would Not subsidised if patient is also receive additional benefit receiving treatment Spacers are with a available
$
propionate
INDACATER OL
Onbrez Breezhale r®
$
Combination Long-Actin g Muscarinic + Long-Actin Antagonists g Beta2 Agonists (LAMA) (LABA) TIOTROPIU
Spiolto Respimat®
$ 50 mcg 100 Note: Beclazone®
Combination Inhaled Corticoste + Long-Actin g Beta2 Agonistsroids (ICS) FLUTICASO (LABA) NE
$
25 mcg Aerosol inhaler
BECLOMET HASONE dipropionat e Qvar®
$ 400 mcg
Dry powder
200/25 inhaler
(LABA)
Oxis®
$
RELIEVER
$
200/6 400/12* Turbuhaler®
Thoracic Society
$ 18 mcg Handihaler®
Antagonists (LAMA)
UMECLIDIN IUM
Incruse Ellipta®
$ 2.5 mcg Fine mist inhaler
GLYCOPYR RONIUM
Seebri® Breezhaler®
$
$
62.5 mcg
Dry powder Funded by 50 mcg endorsement: inhaler having COPD LAMA inhaler Breezhaler® using spirometry is subsidised (i.e. COPD documented only for patients if spirometry is possible, who have been as indication Not subsidised diagnosed as on prescription). and the prescription if patient is also is endorsed receiving treatment accordingly with another susidised LAMA.
Combination Inhaled Corticoste Antagonist roids (LAMA) + Long-Actin(ICS) + Long-Actin g Beta2 Agonist g Muscarinic FLUTICASO (LABA) NE furoate UMECLIDIN + IUM + VILANTERO L Trelegy
Ellipta®
BUDESONI DE + GLYCOPYR RONIUM + FORMOTER OL
Breztri Aerospher e®
$ 100 mcg/62.5 mcg/25 mcg Dry powder inhaler
$ 160 mcg/7.2
Funded via mcg/5 Special Authority: Aerosol inhaler mcg with a diagnosis ICS + LAMA + LABA ‘triple acceptable resultsof COPD confirmed by therapy’ inhaler spirometry, are not possible and meets the and the patient or spirometry has been is subsidised only for patients attempted and is currently on • Patient has following clinical criteria: technically an ICS/LABA a • Patient has COPD Assessment Test or a LAMA/LABA, (CAT) had 2 or more • Patient has exacerbations score greater than 10, had one exacerbation or in the previous • Patient has 12 months, requiring hospitalisation had an eosinophil or or the patient count greater in the previous is 12 months, the clinical criteriacurrently receiving multiple than or equal to 0.3 or x 10^9 cells/L inhaler above prior in the previous to starting multiple triple therapy (ICS/LAMA/LAB 12 months inhaler triple A) and met at therapy. Funding information least one of updated as of 1 June 2025.
Visit www.ph armac.govt.nz of Australia and New Zealand
position statement.
Respirology,
2025.
RELIEVERS
100 mcg/20 mcg Aerosol inhaler
Beclazone®
$ 200 mcg Turbuhaler®
+ PREVEN
BUDESONI DE + FORMOTER OL DuoResp
TER
Combination Inhaled Corticoste + Long-Actin g Beta2 Agonistsroids (ICS) (LABA)
$
$
20 mcg Aerosol inhaler
Inhaled Corticoste roids (ICS)
(FOR COPD)
$
HFA®
$
250 mcg Turbuhaler®
SAMA
SALBUTAM OL + IPRATROPIU M Duolin
Atrovent®
DO
WNLOAD AT: asthmafoundati on.org.nz
CONTROLLERS
$
125 mcg 250 mcg Aerosol inhaler
Symbicort®
asthmaand respiratory .org.nz
Combination SABA +
IPRATROPIU M
$
Pulmicort®
$ 50 mcg
Funded
Short-Acting Muscarinic Antagonists (SAMA)
Bricanyl®
$
100 mcg Aerosol inhaler
Flixotide®
$
(SABA)
TERBUTALIN E
Ventolin®
$
+ PREVENTER
SALBUTAM OL
SalAir®
inhaler
FLUTICASO NE propionate
100/6
CATION
Short-Acting Beta2 Agonists
®
$ 200/6 Dry powder
®
SYMPTOM
100/6 200/6 Turbuhaler
DuoResp Spiromax
$
LONG-ACTING
$
CONTROLLER
(AIR) Therapy
BUDESONI DE + FORMOTER OL
Symbicort®
PREVENTERS
INHALER DEV
Anti-Inflam matory Reliever
NEW!
UPDATED INHALER IDENTIFICATION CHART INSIDE